Search

Displaying results 2281 - 2290 of 3483 in total
  1. Drug

    Sphingosine

    go.drugbank.com/drugs/DB03203
    Investigational

    An amino alcohol with a long unsaturated hydrocarbon chain. Sphingosine and its derivative sphinganine are the major bases of the sphingolipids in mammals. (Dorland, 28th ed)

    Categories: P-glycoprotein substrates
  2. Drug

    Paltusotine

    go.drugbank.com/drugs/DB16277
    ApprovedInvestigational

    Paltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth hormone (GH) and decreases the pro...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  3. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, whi...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  4. Drug

    Azasetron

    go.drugbank.com/drugs/DB16837
    Investigational

    Categories: P-glycoprotein substrates
  5. Drug

    Naringin

    go.drugbank.com/drugs/DB16859
    Experimental

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A Inhibitors
  6. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    Patients with congenital adrenal hyperplasia (CAH) face two major problems: adrenal insufficiency, caused by insufficient endogenous cortisol production, and androgen excess, caused by a counter-regulatory overproduction of adrenocortico...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  7. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    Imlunestrant is a brain-penetrant selective estrogen receptor antagonist and degrader. The FDA approved imlunestrant on September 25, 2025 as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-muta...

    Synonyms: (5r)-5-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-8-(trifluoromethyl)-5h-(1)benzopyrano(4,3-c)quinolin-2-ol, 5h-(1)benzopyrano(4,3-c)quinolin-2-ol, 5-(4-(2-(3-(fluoromethyl)-1-azetidinyl)ethoxy)phenyl)-8-(trifluoromethyl)-, (5r)-Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  8. Drug

    Benzgalantamine

    go.drugbank.com/drugs/DB19353
    ApprovedInvestigational

    Benzgalantamine is a prodrug of galantamine. Gastrointestinal adverse effects are the most frequently reported side effects in patients undergoing treatment with cholinesterase inhibitors, including galantamine, and are often a reason fo...

    Synonyms: 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, benzoate (ester), (4as,6r,8as)-Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  9. Drug

    Hydrastine

    go.drugbank.com/drugs/DB19354
    Experimental

    Synonyms: Phthalide (s)-6,7-dimethoxy-3-(r)-(5,6,7,8-tetrahydro-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (s)-6,7-dimethoxy-3-(r)-(6-methyl-5,6,7,8-tetrahydro-(1,3)dioxolo(4,5-g)isoquinolin-5-yl)isobenzofuran-1(3h)-oneCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Substrates
  10. Drug

    L-lysyl-l-arginine

    go.drugbank.com/drugs/DB19436
    Investigational

    L-lysyl-l-arginine is under investigation in clinical trial NCT03972488 (Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET).

    Synonyms: L-lysyl-l-arginine, L-arginine, l-lysyl-